Core Insights - Nuwellis, Inc. has expanded its pediatric footprint to 47 centers nationwide, including six of the top 10 children's hospitals, highlighting the strategic importance of this category [2][3] Pediatric Growth - The pediatric category now accounts for approximately 50% of total U.S. revenue, marking a significant milestone for the company [2] - Strong utilization is observed within established programs, with growing interest from additional centers for precision fluid management solutions for complex pediatric patients [2][4] Aquadex Therapy Platform - The Aquadex therapy platform is FDA-cleared for use in pediatric and adult patients weighing 20 kg and above, designed for precise ultrafiltration to manage fluid overload in critically ill children [3] - Continued pediatric expansion is viewed as a strategic growth catalyst, supported by high-acuity use cases and institutional adoption [3][4] Institutional Adoption - Adoption within leading pediatric centers reflects the increasing recognition of the need for precision fluid management in vulnerable populations [4] - The company aims to support clinical evidence development and expand market access as part of its strategy [4] Company Overview - Nuwellis, Inc. focuses on advancing precision fluid management technologies across the cardiorenal continuum, developing solutions for both acute and chronic care settings [5] - The company's portfolio includes technologies addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [5] Aquadex SmartFlow System - The Aquadex SmartFlow system is indicated for temporary or extended use in patients weighing 20 kg or more, specifically for those whose fluid overload is unresponsive to medical management [6] - Treatments must be administered by trained healthcare providers in clinical settings under physician prescription [6]

Core Insights - Nuwellis, Inc. experienced a year of structural change and strategic re-focus in 2025, with a decline in full-year revenue compared to 2024, but fourth-quarter results showed stronger utilization trends and gross margin expansion [3][4] Fourth Quarter Highlights - Revenue for Q4 2025 was $2.4 million, reflecting a 4% increase year-over-year and a 9% increase sequentially, driven by a 208% increase in U.S. console sales and an 11% increase in circuit average selling price [4][8] - Gross margin improved to 68.2% in Q4 2025 from 58.4% in the prior-year quarter, attributed to better pricing and product mix [5][8] - Operating expenses for Q4 2025 were approximately $4.1 million, up from approximately $3.7 million in the prior-year quarter, resulting in an operating loss of approximately $2.4 million, consistent with the prior-year quarter [5][6] Full Year Financial Results - Total revenue for the full year 2025 was $8.3 million, a 5% decrease from the previous year, with Heart Failure revenue increasing by 8% and Pediatrics by 14%, while Critical Care revenue declined by 19% [7][9] - The gross margin for the full year was 62.0%, down from 64.9% in the prior year [7] - The net loss attributable to common shareholders for the full year was approximately $17.5 million, which included a $6.4 million non-cash warrant valuation expense [9] Strategic Developments - The company is entering 2026 with new momentum, including the acquisition of Rendiatech, the appointment of a new Chief Financial Officer, and additional capital to support operations [3][8] - The focus for 2026 includes integrating the Rendiatech acquisition, developing Vivian, a novel pediatric solution, and enhancing commercial execution [3]

Core Insights - Nuwellis, Inc. has appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy to enhance its clinical leadership in precision fluid management and acute kidney injury [1][4] Company Overview - Nuwellis, Inc. is a medical technology company focused on delivering solutions for patients with cardiorenal conditions, emphasizing precision fluid management technologies [7] - The company develops solutions that support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings [7] Appointment of Dr. Goldstein - Dr. Goldstein is a recognized leader in pediatric nephrology and critical care medicine, serving as Director of the Center for Acute Care Nephrology and holding a prestigious chair at Cincinnati Children's Hospital [2] - His research has significantly influenced the understanding of acute kidney injury (AKI) and fluid overload, shaping global standards for their management [3] Strategic Focus - As Director of Clinical Strategy, Dr. Goldstein will provide clinical feedback, guide product development, and support educational initiatives aligned with Nuwellis' cardiorenal focus [4] - The company's strategy emphasizes early identification of fluid overload and the use of technologies designed to safely remove excess fluid while maintaining hemodynamic stability [5] Product Highlight - The Aquadex SmartFlow system is a key product that offers a clinically proven method for removing excess fluid from patients suffering from hypervolemia, indicated for both adult and pediatric patients [8]

Core Insights - Nuwellis, Inc. has appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026, enhancing the board's expertise in public company leadership, capital markets, and medical device commercialization [1][2] Group 1: Board Appointments - The appointments are aimed at reinforcing operational discipline and long-term value creation for the company [2] - Martin J. Emerson has extensive experience in leading medical device organizations and has successfully guided companies through strategic transformations and acquisitions [3][4] - David A. McDonald brings over 25 years of experience in healthcare capital markets and corporate development, having raised nearly $200 million in capital during his career [5][6] Group 2: Company Overview - Nuwellis, Inc. focuses on advancing precision fluid management technologies for cardiorenal conditions, developing solutions for patient care through monitoring, therapy, and data-informed clinical decision-making [7] - The company's portfolio includes both commercially available and development-stage technologies aimed at addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [7] Group 3: Product Highlight - The Aquadex SmartFlow system is designed to remove excess fluid from patients suffering from hypervolemia, indicated for both temporary and extended use in adult and pediatric patients [8]

Core Insights - Nuwellis, Inc. has appointed Carisa Schultz as Chief Financial Officer, effective February 2, 2026, to enhance its financial leadership in the medical technology sector focused on precision cardiorenal care [1][4]. Company Overview - Nuwellis, Inc. is a medical technology company that develops precision fluid management technologies aimed at improving patient care across the cardiorenal continuum, addressing both acute and chronic conditions [4]. - The company's product portfolio includes both commercially available and development-stage technologies that focus on safety, precision, and scalability for various patient populations [4]. Leadership Experience - Carisa Schultz has extensive experience in healthcare finance, having served as Vice President of Finance at NeueHealth, where she led enterprise finance, treasury, and corporate development [2]. - Schultz's background includes roles at Boston Scientific and various leadership positions in public and private healthcare organizations, along with experience in Big Four public accounting [3]. Product Highlight - The Aquadex SmartFlow® System is designed to remove excess fluid from patients suffering from hypervolemia, with indications for both temporary and extended use in adult and pediatric patients [5].

Core Viewpoint - Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., enhancing its capabilities in real-time kidney function monitoring and expanding its cardiorenal platform [1][2]. Group 1: Transaction Details - The acquisition of Rendiatech is expected to close upon meeting customary closing conditions, positioning Nuwellis to broaden its portfolio into real-time renal diagnostics [1][5]. - The transaction has been approved by the boards of directors of both Nuwellis and Rendiatech [5]. Group 2: Strategic Implications - This acquisition represents a strategic move for Nuwellis, allowing the company to extend its capabilities beyond therapeutic fluid management into real-time renal monitoring, which aligns with its long-term vision [2][4]. - Nuwellis plans to leverage its existing commercial infrastructure and clinical relationships to integrate Rendiatech's technology effectively [4]. Group 3: Technology Overview - Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement, aiming to replace manual collection methods [3][9]. - The addition of the Clarity system is expected to lay the groundwork for future advancements in urine-based analytics and comprehensive kidney function assessment [3].

Core Viewpoint - Nuwellis, Inc. has appointed Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026, while three members resigned from the board, with no disagreements reported [1][4][5]. Group 1: Board Appointments - Katharyn Field is the CEO of ISpecimen Inc. and has held various leadership roles in other companies, including Halo Collective and Marimed Inc. She holds an MBA from Columbia Business School and a BA from Stanford University [2]. - Mika Grasso is an Investment Manager at a private family office with prior experience at Zions Capital Markets, Paulson Investment Company, Goldman Sachs, and Power Systems Management. He holds an MS in Finance and a BS in Business Administration from the University of Colorado Boulder [3]. Group 2: Board Resignations - Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the board effective January 21, 2026, with the company confirming that these resignations were not due to any disagreements regarding operations or policies [4][5]. Group 3: Company Overview - Nuwellis, Inc. is a medical technology company focused on precision fluid management technologies for cardiorenal care, developing solutions for both acute and chronic care settings [6]. - The company's portfolio includes technologies addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [6].

Core Insights - Nuwellis, Inc. has received a notice of allowance for a new patent related to advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, specifically for the Vivian Pediatric Continuous Renal Replacement Therapy (CRRT) System [1][3] - The patented technology enhances safety by dynamically adjusting clamping force based on environmental factors and improving material stability through thermal insulation [2] - The company emphasizes its commitment to pediatric innovation and safety, with a growing portfolio of intellectual property supporting the Vivian system [3][4] Company Overview - Nuwellis, Inc. is a medical technology company focused on solutions for patients with cardio-renal conditions, headquartered in Minneapolis with a subsidiary in Ireland [6] - The company is dedicated to transforming the lives of patients suffering from fluid overload through innovative therapies, including the Aquadex SmartFlow system [6][7] Product Details - The Aquadex SmartFlow system is designed for ultrafiltration therapy in patients with fluid overload, indicated for both temporary and extended use in adults and pediatric patients weighing 20 kg or more [7] - The Vivian system is a pediatric CRRT platform designed for neonates and children, featuring integrated sensors for real-time monitoring and multiple therapy options [8]

Core Viewpoint - Nuwellis, Inc. has announced a postponement of its 2025 second quarter earnings release and conference call, originally set for August 12, 2025, due to the need for additional time to complete valuations and audit procedures [1] Company Overview - Nuwellis, Inc. is a medical technology company focused on fluid management, specifically targeting patients suffering from fluid overload [3] - The company is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [3] Product Information - The Aquadex SmartFlow® system is designed for ultrafiltration therapy, providing a clinically proven method to remove excess fluid from patients with hypervolemia [4] - The system is indicated for temporary use (up to 8 hours) or extended use (longer than 8 hours) in adult and pediatric patients weighing 20 kg or more, whose fluid overload is unresponsive to medical management [4] Upcoming Events - A conference call and webcast to discuss financial results and provide a general business update is scheduled for 9:00 AM ET on August 14, 2025 [1]